405
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Evaluation of Excess Significance Bias in Animal Studies of Neurological Diseases

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The evaluation of 160 meta-analyses of animal studies on potential treatments for neurological disorders reveals that the number of statistically significant results was too large to be true, suggesting biases.

          Abstract

          Animal studies generate valuable hypotheses that lead to the conduct of preventive or therapeutic clinical trials. We assessed whether there is evidence for excess statistical significance in results of animal studies on neurological disorders, suggesting biases. We used data from meta-analyses of interventions deposited in Collaborative Approach to Meta-Analysis and Review of Animal Data in Experimental Studies (CAMARADES). The number of observed studies with statistically significant results (O) was compared with the expected number (E), based on the statistical power of each study under different assumptions for the plausible effect size. We assessed 4,445 datasets synthesized in 160 meta-analyses on Alzheimer disease ( n = 2), experimental autoimmune encephalomyelitis ( n = 34), focal ischemia ( n = 16), intracerebral hemorrhage ( n = 61), Parkinson disease ( n = 45), and spinal cord injury ( n = 2). 112 meta-analyses (70%) found nominally ( p≤0.05) statistically significant summary fixed effects. Assuming the effect size in the most precise study to be a plausible effect, 919 out of 4,445 nominally significant results were expected versus 1,719 observed ( p<10 −9). Excess significance was present across all neurological disorders, in all subgroups defined by methodological characteristics, and also according to alternative plausible effects. Asymmetry tests also showed evidence of small-study effects in 74 (46%) meta-analyses. Significantly effective interventions with more than 500 animals, and no hints of bias were seen in eight (5%) meta-analyses. Overall, there are too many animal studies with statistically significant results in the literature of neurological disorders. This observation suggests strong biases, with selective analysis and outcome reporting biases being plausible explanations, and provides novel evidence on how these biases might influence the whole research domain of neurological animal literature.

          Author Summary

          Studies have shown that the results of animal biomedical experiments fail to translate into human clinical trials; this could be attributed either to real differences in the underlying biology between humans and animals, to shortcomings in the experimental design, or to bias in the reporting of results from the animal studies. We use a statistical technique to evaluate whether the number of published animal studies with “positive” (statistically significant) results is too large to be true. We assess 4,445 animal studies for 160 candidate treatments of neurological disorders, and observe that 1,719 of them have a “positive” result, whereas only 919 studies would a priori be expected to have such a result. According to our methodology, only eight of the 160 evaluated treatments should have been subsequently tested in humans. In summary, we judge that there are too many animal studies with “positive” results in the neurological disorder literature, and we discuss the reasons and potential remedies for this phenomenon.

          Related collections

          Most cited references21

          • Record: found
          • Abstract: found
          • Article: not found

          A call for transparent reporting to optimize the predictive value of preclinical research.

          The US National Institute of Neurological Disorders and Stroke convened major stakeholders in June 2012 to discuss how to improve the methodological reporting of animal studies in grant applications and publications. The main workshop recommendation is that at a minimum studies should report on sample-size estimation, whether and how animals were randomized, whether investigators were blind to the treatment, and the handling of data. We recognize that achieving a meaningful improvement in the quality of reporting will require a concerted effort by investigators, reviewers, funding agencies and journal editors. Requiring better reporting of animal studies will raise awareness of the importance of rigorous study design to accelerate scientific progress.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Recommendations for standards regarding preclinical neuroprotective and restorative drug development.

            (1999)
            The plethora of failed clinical trials with neuroprotective drugs for acute ischemic stroke have raised justifiable concerns about how best to proceed for the future development of such interventions. Preclinical testing of neuroprotective drugs is an important aspect of assessing their therapeutic potential, but guidelines concerning how to perform preclinical development of purported neuroprotective drugs for acute ischemic stroke are lacking. This conference of academicians and industry representatives was convened to suggest such guidelines for the preclinical evaluation of neuroprotective drugs and to recommend to potential clinical investigators the data they should review to reassure themselves that a particular neuroprotective drug has a reasonable chance to succeed in an appropriately designed clinical trial. Without rigorous, robust, and detailed preclinical evaluation, it is unlikely that novel neuroprotective drugs will prove to be effective when tested in large, time-consuming, and expensive clinical trials. Additionally, similar recommendations are provided for drugs with the potential to enhance recovery after acute ischemic stroke, a burgeoning new field with great potential but little currently available data. The suggestions contained in this document are meant to serve as overall guidelines that must be adapted to the individual characteristics related to particular drugs and their preclinical and clinical development needs.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Where is the evidence that animal research benefits humans?

                Bookmark

                Author and article information

                Contributors
                Role: Academic Editor
                Journal
                PLoS Biol
                PLoS Biol
                plos
                plosbiol
                PLoS Biology
                Public Library of Science (San Francisco, USA )
                1544-9173
                1545-7885
                July 2013
                July 2013
                16 July 2013
                : 11
                : 7
                : e1001609
                Affiliations
                [1 ]Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece
                [2 ]Department of Clinical Neurosciences, University of Edinburgh, Edinburgh, United Kingdom
                [3 ]The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Heidelberg, Victoria, Australia
                [4 ]Department of Methods and Experimental Psychology, University of Deusto, Bilbao, Spain
                [5 ]Laboratory of Cognitive Neuroscience, School of Psychology, Aristotle University of Thessaloniki, Thessaloniki, Greece
                [6 ]Stanford Prevention Research Center, Department of Medicine, and Department of Health Research and Policy, Stanford University School of Medicine, and Department of Statistics, Stanford University School of Humanities and Sciences, Stanford, California, United States of America
                University of California San Francisco, United States of America
                Author notes

                The authors have declared that no competing interests exist.

                The author(s) have made the following declarations about their contributions: Conceived and designed the experiments: KT ES MM JI. Analyzed the data: KT OP EA EE. Wrote the paper: KT OP JI. Designed and supervised the CAMARADES database: ES DH RS MM.

                Article
                PBIOLOGY-D-13-00576
                10.1371/journal.pbio.1001609
                3712913
                23874156
                28853015-33ac-4696-828f-7568fa2dd27d
                Copyright @ 2013

                This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

                History
                : 13 February 2013
                : 6 June 2013
                Page count
                Pages: 10
                Funding
                No specific and/or direct funding was received for this study. No funding bodies played any role in the design, writing or decision to publish this manuscript. The authors were personally salaried by their institutions during the period of writing though no specific salary was set aside or given for the writing of this paper. There are no current external funding sources for this study.
                Categories
                Research Article
                Medicine
                Epidemiology
                Clinical Epidemiology
                Neurology
                Dementia
                Parkinson Disease
                Spinal Cord Diseases

                Life sciences
                Life sciences

                Comments

                Comment on this article